JP2001514665A5 - - Google Patents

Download PDF

Info

Publication number
JP2001514665A5
JP2001514665A5 JP1998539793A JP53979398A JP2001514665A5 JP 2001514665 A5 JP2001514665 A5 JP 2001514665A5 JP 1998539793 A JP1998539793 A JP 1998539793A JP 53979398 A JP53979398 A JP 53979398A JP 2001514665 A5 JP2001514665 A5 JP 2001514665A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998539793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514665A (ja
Filing date
Publication date
Priority claimed from US08/814,386 external-priority patent/US6030961A/en
Application filed filed Critical
Publication of JP2001514665A publication Critical patent/JP2001514665A/ja
Publication of JP2001514665A5 publication Critical patent/JP2001514665A5/ja
Ceased legal-status Critical Current

Links

JP53979398A 1997-03-11 1998-03-11 オキシアルキレンホスフェート化合物およびその使用 Ceased JP2001514665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/814,386 1997-03-11
US08/814,386 US6030961A (en) 1997-03-11 1997-03-11 Oxyalkylene phosphate compounds and uses thereof
PCT/US1998/004834 WO1998040080A1 (en) 1997-03-11 1998-03-11 Oxyalkylene phosphate compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2001514665A JP2001514665A (ja) 2001-09-11
JP2001514665A5 true JP2001514665A5 (https=) 2005-10-06

Family

ID=25214915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53979398A Ceased JP2001514665A (ja) 1997-03-11 1998-03-11 オキシアルキレンホスフェート化合物およびその使用

Country Status (8)

Country Link
US (1) US6030961A (https=)
EP (1) EP0986391A4 (https=)
JP (1) JP2001514665A (https=)
KR (1) KR20000076151A (https=)
AU (1) AU6459798A (https=)
CA (1) CA2283162A1 (https=)
IL (1) IL131742A (https=)
WO (1) WO1998040080A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US20020120008A1 (en) * 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
IL137672A0 (en) * 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
AU2001296677A1 (en) * 2000-10-05 2002-04-15 Temple University - Of The Commonwealth System Of Higher Education Substituted (e)-styryl benzylsulfones for treating proliferative disorders
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
HU229521B1 (hu) 2001-08-21 2014-01-28 Astellas Pharma Inc A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
EP1443928B1 (en) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
WO2003033678A2 (en) * 2001-10-18 2003-04-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR100924737B1 (ko) 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005087216A2 (de) * 2004-03-12 2005-09-22 Eberhard-Karls-Universität Tübingen Behandlung von anämischen zuständen durch inhibierung der erythrozytenapoptose
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2008083288A2 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals Purifiction of romidepsin
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
CA3142142A1 (en) 2019-05-31 2020-12-03 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944898A (en) * 1957-11-27 1960-07-12 Eastman Kodak Co Sensitization of photographic emulsions
US3219630A (en) * 1961-08-25 1965-11-23 Tenneco Chem Production of branched chain polyoxymethylene polycarboxylates
US3293220A (en) * 1962-10-11 1966-12-20 Toyo Rayon Co Ltd Process for heat stabilization of polyoxymethylene
FR1386096A (fr) * 1963-03-26 1965-01-15 Heyden Newport Chemical Corp Perfectionnements apportés aux procédés pour la production de dicarboxylates de méthylène
US3336262A (en) * 1965-11-05 1967-08-15 Tenneco Chem Branched chain polyoxymethylene polycarboxylates
FR1540418A (fr) * 1966-07-21 1968-09-27 Asahi Chemical Ind Procédé pour la préparation d'aldéhydes et d'anhydrides d'acides
US3574714A (en) * 1967-02-22 1971-04-13 Sumitomo Chemical Co Alpha,alpha-diacyloxy-2,3,4,5,6-pentachlorotoluene derivatives
GB1220447A (en) * 1967-04-19 1971-01-27 Wyeth John & Brother Ltd Salicylic acid derivatives
US3720706A (en) * 1972-01-24 1973-03-13 Chevron Res Methylene and oxymethylene bis-ester production
US3812176A (en) * 1972-01-24 1974-05-21 Chevron Res Methylene and oxymethylene bis-ester production
CA1012885A (en) * 1972-06-28 1977-06-28 Chevron Research And Technology Company Fungus and mold control
US3931412A (en) * 1972-06-28 1976-01-06 Chevron Research Company Fungus and bacteria control with di-carboxylic acid esters
DE2417143C2 (de) * 1974-04-09 1982-04-15 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von (Thio) Phosphor(Phosphon)säureestern
US4123552A (en) * 1974-05-09 1978-10-31 Chevron Research Company Compositions for preserving crops and animal feedstuffs
US4012526A (en) * 1974-05-09 1977-03-15 Chevron Research Company Oxymethylene di-carboxylic acid esters as anti-fungal agents and animal growth promoters
US4215215A (en) * 1975-08-01 1980-07-29 Hoffmann-La Roche Inc. 9-Phenyl-nonate traene compounds
US4105681A (en) * 1975-08-01 1978-08-08 Hoffmann-La Roche Inc. 9-phenyl 5,6-dimethyl-nona-2,4,6,8-tetraeonic acid compounds
US4198416A (en) * 1976-09-30 1980-04-15 Meiji Seika Kaisha, Ltd. 5-Alkoxy-picolinic esters and anti-hypertensive composition containing 5-alkoxy-picolinic esters
EP0056189B1 (en) * 1980-12-26 1986-08-20 Ss Pharmaceutical Co., Ltd. 2,3-butanediol diester derivatives, process for producing the same, and an antiulcer drug containing the same
JPS5815912A (ja) * 1981-07-22 1983-01-29 Ss Pharmaceut Co Ltd 消炎鎮痛剤
GB2126082A (en) * 1982-08-12 1984-03-21 Heinrich Schulze Pharmaceutical preparations having analgetic and cytostatic activity
CA1201127A (en) * 1982-09-10 1986-02-25 Katsuhiro Uchida Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US5196567A (en) * 1983-02-19 1993-03-23 Kaken Pharmaceutical Co., Ltd. Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same
GB8310080D0 (en) * 1983-04-14 1983-05-18 Interox Chemicals Ltd Bleach composition
GB8310081D0 (en) * 1983-04-14 1983-05-18 Interox Chemicals Ltd Peroxygen compounds
JPS601122A (ja) * 1983-06-20 1985-01-07 Green Cross Corp:The ビフエニリルプロピオン酸誘導体脂肪乳剤
US4760057A (en) * 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK498487A (da) * 1986-10-06 1988-04-07 Hoffmann La Roche Hidtil ukendte retinoider
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
JPS63101348A (ja) * 1986-10-20 1988-05-06 Idemitsu Kosan Co Ltd １，１−ジエステルの製造方法
US4885311A (en) * 1987-06-29 1989-12-05 Molecular Design International Topical transretinoids for treatment of acne and skin diseases
EP0302349B1 (en) * 1987-07-30 1993-09-29 Bar Ilan University Biologically active carboxylic acid esters
FR2633929B2 (fr) * 1987-09-25 1995-05-24 Picardie Universite Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
EP0371789B1 (en) * 1988-11-29 1997-01-02 Children's Hospital Medical Center Of Northern California Medicament for augmenting fetal hemoglobin
CA2037150C (en) * 1990-03-27 1999-12-28 Guenter Gross Retinoids
US5216004A (en) * 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
WO1993019778A1 (en) * 1992-04-07 1993-10-14 The Scripps Research Institute Method for inducing tolerance to an antigen using butyrate
US5569675A (en) * 1994-03-07 1996-10-29 Bar Ilan University Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
US5710176A (en) * 1994-09-16 1998-01-20 Bar-Ilan University Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases

Similar Documents

Publication Publication Date Title
JP2000509637A5 (https=)
JP2000510751A5 (https=)
JP2000509912A5 (https=)
JP2000509635A5 (https=)
JP2000509942A5 (https=)
JP2001519787A5 (https=)
JP2001500351A5 (https=)
JP2000509587A5 (https=)
JP2002508781A5 (https=)
JP2001524940A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2001514665A5 (https=)
JP2000508841A5 (https=)
JP2001526765A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2001506336A5 (https=)
JP2000509755A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)
JP2000508836A5 (https=)
JP2000508102A5 (https=)
JP2000509520A5 (https=)